189 related articles for article (PubMed ID: 23591748)
1. Engineered mannitol ternary additives improve dispersion of lactose-salbutamol sulphate dry powder inhalations.
Kaialy W; Nokhodchi A
AAPS J; 2013 Jul; 15(3):728-43. PubMed ID: 23591748
[TBL] [Abstract][Full Text] [Related]
2. Spray-Congealing and Wet-Sieving as Alternative Processes for Engineering of Inhalation Carrier Particles: Comparison of Surface Properties, Blending and In Vitro Performance.
Pinto JT; Zellnitz S; Guidi T; Schiaretti F; Schroettner H; Paudel A
Pharm Res; 2021 Jun; 38(6):1107-1123. PubMed ID: 34114162
[TBL] [Abstract][Full Text] [Related]
3. The influence of physical properties and morphology of crystallised lactose on delivery of salbutamol sulphate from dry powder inhalers.
Kaialy W; Martin GP; Larhrib H; Ticehurst MD; Kolosionek E; Nokhodchi A
Colloids Surf B Biointerfaces; 2012 Jan; 89():29-39. PubMed ID: 21962946
[TBL] [Abstract][Full Text] [Related]
4. Dry powder inhalers: physicochemical and aerosolization properties of several size-fractions of a promising alterative carrier, freeze-dried mannitol.
Kaialy W; Nokhodchi A
Eur J Pharm Sci; 2015 Feb; 68():56-67. PubMed ID: 25497318
[TBL] [Abstract][Full Text] [Related]
5. Effect of carrier particle shape on dry powder inhaler performance.
Kaialy W; Alhalaweh A; Velaga SP; Nokhodchi A
Int J Pharm; 2011 Dec; 421(1):12-23. PubMed ID: 21945739
[TBL] [Abstract][Full Text] [Related]
6. Co-spraying of carriers (mannitol-lactose) as a method to improve aerosolization performance of salbutamol sulfate dry powder inhaler.
Ferdynand MS; Nokhodchi A
Drug Deliv Transl Res; 2020 Oct; 10(5):1418-1427. PubMed ID: 31933129
[TBL] [Abstract][Full Text] [Related]
7. Dry powder inhaler performance of spray dried mannitol with tailored surface morphologies as carrier and salbutamol sulphate.
Mönckedieck M; Kamplade J; Fakner P; Urbanetz NA; Walzel P; Steckel H; Scherließ R
Int J Pharm; 2017 May; 524(1-2):351-363. PubMed ID: 28347847
[TBL] [Abstract][Full Text] [Related]
8. Dry powder inhalers: mechanistic evaluation of lactose formulations containing salbutamol sulphate.
Kaialy W; Ticehurst M; Nokhodchi A
Int J Pharm; 2012 Feb; 423(2):184-94. PubMed ID: 22197772
[TBL] [Abstract][Full Text] [Related]
9. Towards a more desirable dry powder inhaler formulation: large spray-dried mannitol microspheres outperform small microspheres.
Kaialy W; Hussain T; Alhalaweh A; Nokhodchi A
Pharm Res; 2014 Jan; 31(1):60-76. PubMed ID: 23918220
[TBL] [Abstract][Full Text] [Related]
10. Antisolvent crystallisation is a potential technique to prepare engineered lactose with promising aerosolisation properties: effect of saturation degree.
Kaialy W; Nokhodchi A
Int J Pharm; 2012 Nov; 437(1-2):57-69. PubMed ID: 22884837
[TBL] [Abstract][Full Text] [Related]
11. The enhanced aerosol performance of salbutamol from dry powders containing engineered mannitol as excipient.
Kaialy W; Martin GP; Ticehurst MD; Momin MN; Nokhodchi A
Int J Pharm; 2010 Jun; 392(1-2):178-88. PubMed ID: 20363301
[TBL] [Abstract][Full Text] [Related]
12. Engineered mannitol as an alternative carrier to enhance deep lung penetration of salbutamol sulphate from dry powder inhaler.
Kaialy W; Momin MN; Ticehurst MD; Murphy J; Nokhodchi A
Colloids Surf B Biointerfaces; 2010 Sep; 79(2):345-56. PubMed ID: 20537870
[TBL] [Abstract][Full Text] [Related]
13. Potential and constraints for the application of CFD combined with Lagrangian particle tracking to dry powder inhalers.
Sommerfeld M; Cui Y; Schmalfuß S
Eur J Pharm Sci; 2019 Feb; 128():299-324. PubMed ID: 30553814
[TBL] [Abstract][Full Text] [Related]
14. The use of different sugars as fine and coarse carriers for aerosolised salbutamol sulphate.
Tee SK; Marriott C; Zeng XM; Martin GP
Int J Pharm; 2000 Nov; 208(1-2):111-23. PubMed ID: 11064216
[TBL] [Abstract][Full Text] [Related]
15. Elucidation of lactose fine size and drug shape on rheological properties and aerodynamic behavior of dry powders for inhalation.
Sun Y; Yu D; Li J; Zhao J; Feng Y; Zhang X; Mao S
Eur J Pharm Biopharm; 2022 Oct; 179():47-57. PubMed ID: 36029939
[TBL] [Abstract][Full Text] [Related]
16. Development of drug alone and carrier-based GLP-1 dry powder inhaler formulations.
Babenko M; Alany RG; Calabrese G; Kaialy W; ElShaer A
Int J Pharm; 2022 Apr; 617():121601. PubMed ID: 35181460
[TBL] [Abstract][Full Text] [Related]
17. Particle engineered mannitol for carrier-based inhalation - A serious alternative?
Hertel N; Birk G; Scherließ R
Int J Pharm; 2020 Mar; 577():118901. PubMed ID: 31846726
[TBL] [Abstract][Full Text] [Related]
18. The effect of engineered mannitol-lactose mixture on dry powder inhaler performance.
Kaialy W; Larhrib H; Martin GP; Nokhodchi A
Pharm Res; 2012 Aug; 29(8):2139-56. PubMed ID: 22477070
[TBL] [Abstract][Full Text] [Related]
19. Characterisation and deposition studies of recrystallised lactose from binary mixtures of ethanol/butanol for improved drug delivery from dry powder inhalers.
Kaialy W; Martin GP; Ticehurst MD; Royall P; Mohammad MA; Murphy J; Nokhodchi A
AAPS J; 2011 Mar; 13(1):30-43. PubMed ID: 21057906
[TBL] [Abstract][Full Text] [Related]
20. Carrier-based dry powder inhalation: Impact of carrier modification on capsule filling processability and in vitro aerodynamic performance.
Faulhammer E; Wahl V; Zellnitz S; Khinast JG; Paudel A
Int J Pharm; 2015 Aug; 491(1-2):231-42. PubMed ID: 26136200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
